$NPHC Nutra Pharma Provides Updates on Improvement
Post# of 102
https://www.newsfilecorp.com/release/85494
Nutra Pharma is providing updates on their work in improving manufacturing scale and capabilities for the production of their over-the-counter pain relievers
Plantation, Florida--(Newsfile Corp. - May 27, 2021) - Nutra Pharma Corporation (OTC Pink: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away™, Equine Pain-Away™ and Luxury Feet™ in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, is providing updates today on increasing their manufacturing capabilities for the production of their line of over-the-counter pain relievers and anti-inflammatory drugs.
"We announced earlier this year that we have been in the process of bringing all of our manufacturing in-house," stated Brent Bonner, Warehouse Manager of Nutra Pharma. "As part of this process, we have completed the design and purchase for a new liquid filling line," he continued. "This includes automatic filling, capping, coding, labeling and heat shrinking for most of our products. The new equipment will allow production of up to 40 bottles per minute, which greatly increases our manufacturing capacity. The equipment is expected to be validated, certified and in production by early July. This will allow us to scale up production to meet expected upcoming orders as we increase our sales promotional activities and plan our retail rollout later this year," he concluded.
In addition to Amazon, Walmart Marketplace and the Company's own product websites; Nutra Pharma announced previously their plans to greatly expand online marketing and promotional activity through the use of endorsements from actual product users that include celebrities, internet influencers as well as professional and Olympic athletes.
As Nutra Pharma moves forward with these projects, they will provide further updates throughout the rest of 2021.